| answer text |
<p>A long-lasting, efficacious and cost-effective vaccine would make a major contribution
to malaria control. In October 2014 DFID last received an update on progress from
GlaxoSmithKline (GSK), who have been developing the RTS,S vaccine with the non-profit
PATH Malaria Vaccine Initiative (MVI). We will be looking closely at the results of
the phase III trials of the RTS,S vaccine when they are released and the position
of the World Health Organisation, who will not formally review the evidence and take
a policy decision on the vaccine until 2015.</p><p> </p>
|
 |
